|1.||Yu, Peng: 1 article (08/2014)|
|2.||Zhao, Bao-Lei: 1 article (08/2014)|
|3.||Wang, Hao-Meng: 1 article (08/2014)|
|4.||Fan, Zhen-Chuan: 1 article (08/2014)|
|5.||Wang, Xiao-Hua: 1 article (08/2014)|
|6.||Weyermann, Philipp: 1 article (05/2006)|
|7.||Kohler, Götz: 1 article (05/2006)|
|8.||Nicholson, Janet R: 1 article (05/2006)|
|9.||Senn, Claudia: 1 article (05/2006)|
|10.||Hofbauer, Karl G: 1 article (05/2006)|
05/01/2006 - "In contrast, the tumor-bearing mice treated with ML00253764 maintained their LBM. "
03/25/2004 - "Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model."
|2.||Weight Loss (Weight Reduction)
08/01/2014 - "As tested with 12 obesity-causing human MC4R variants including S58C, E61K, N62S, I69T, P78L, C84R, G98R, T162I, R165W, W174C, C271Y, and P299H, Ipsen 17 was found to be the most universal pharmacological chaperone of MC4R reported so far because it can completely rescue nearly all mutant receptors (except P299H) with the highest potency (an EC50 value of approximately 10(-8) M) and efficiency when compared with results for other tested pharmacological chaperones of MC4R including ML00253764, PBA, MTHP, PPPone, MPCI, DCPMP, and NBP described in the literature. "
|1.||Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)